Trial Profile

Clinical study of RGN-259 for Dry Eye Disease

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 31 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Timbetasin (Primary)
Indications Dry eyes
Focus Adverse reactions; Diagnostic use
Acronyms ARISE-4
Sponsors ReGenTree

Most Recent Events

24 Oct 2022 According to a RegeneRx Biopharmaceuticals media release, this trial is expected to begin in Q2 2023.
24 Oct 2022 According to a RegeneRx Biopharmaceuticals media release, company submitted a request for the Special Protocol Assessment (SPA) to the U.S. FDA for an in-depth discussion and assessment of the clinical protocol for this trial.
29 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com